Literature DB >> 22896759

Monoclonal antibodies in cancer therapy.

Andrew M Scott1, James P Allison, Jedd D Wolchok.   

Abstract

Entities:  

Keywords:  antibody identification; antigenic targets; tumor surface antigens; tumor therapy

Mesh：

Substances：

Year:  2012        PMID： 22896759      PMCID： PMC3380347     

Source DB:  PubMed          Journal:  Cancer Immun        ISSN： 1424-9634


× No keyword cloud information.
  54 in total

1.  Continuous cultures of fused cells secreting antibody of predefined specificity.

Authors:  G Köhler; C Milstein
Journal:  Nature       Date:  1975-08-07       Impact factor: 49.962

2.  Quantitative analysis of antibody localization in human metastatic colon cancer: a phase I study of monoclonal antibody A33.

Authors:  S Welt; C R Divgi; F X Real; S D Yeh; P Garin-Chesa; C L Finstad; J Sakamoto; A Cohen; E R Sigurdson; N Kemeny
Journal:  J Clin Oncol       Date:  1990-11       Impact factor: 44.544

Review 3.  Immunogenetics of human cell surface differentiation.

Authors:  W J Rettig; L J Old
Journal:  Annu Rev Immunol       Date:  1989       Impact factor: 28.527

4.  Specific targeting, biodistribution, and lack of immunogenicity of chimeric anti-GD3 monoclonal antibody KM871 in patients with metastatic melanoma: results of a phase I trial.

Authors:  A M Scott; F T Lee; W Hopkins; J S Cebon; J M Wheatley; Z Liu; F E Smyth; C Murone; S Sturrock; D MacGregor; N Hanai; K Inoue; M Yamasaki; M W Brechbiel; I D Davis; R Murphy; A Hannah; M Lim-Joon; T Chan; G Chong; G Ritter; E W Hoffman; A W Burgess; L J Old
Journal:  J Clin Oncol       Date:  2001-10-01       Impact factor: 44.544

5.  Ipilimumab and a poxviral vaccine targeting prostate-specific antigen in metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial.

Authors:  Ravi A Madan; Mahsa Mohebtash; Philip M Arlen; Matteo Vergati; Myrna Rauckhorst; Seth M Steinberg; Kwong Y Tsang; Diane J Poole; Howard L Parnes; John J Wright; William L Dahut; Jeffrey Schlom; James L Gulley
Journal:  Lancet Oncol       Date:  2012-02-10       Impact factor: 41.316

6.  Antibody targeting in metastatic colon cancer: a phase I study of monoclonal antibody F19 against a cell-surface protein of reactive tumor stromal fibroblasts.

Authors:  S Welt; C R Divgi; A M Scott; P Garin-Chesa; R D Finn; M Graham; E A Carswell; A Cohen; S M Larson; L J Old
Journal:  J Clin Oncol       Date:  1994-06       Impact factor: 44.544

7.  Antibody localization in human renal cell carcinoma: a phase I study of monoclonal antibody G250.

Authors:  E Oosterwijk; N H Bander; C R Divgi; S Welt; J C Wakka; R D Finn; E A Carswell; S M Larson; S O Warnaar; G J Fleuren
Journal:  J Clin Oncol       Date:  1993-04       Impact factor: 44.544

8.  Phase I and imaging trial of indium 111-labeled anti-epidermal growth factor receptor monoclonal antibody 225 in patients with squamous cell lung carcinoma.

Authors:  C R Divgi; S Welt; M Kris; F X Real; S D Yeh; R Gralla; B Merchant; S Schweighart; M Unger; S M Larson
Journal:  J Natl Cancer Inst       Date:  1991-01-16       Impact factor: 13.506

9.  A phase 1B trial of humanized monoclonal antibody M195 (anti-CD33) in myeloid leukemia: specific targeting without immunogenicity.

Authors:  P C Caron; J G Jurcic; A M Scott; R D Finn; C R Divgi; M C Graham; I M Jureidini; G Sgouros; D Tyson; L J Old
Journal:  Blood       Date:  1994-04-01       Impact factor: 22.113

10.  Reshaping human antibodies for therapy.

Authors:  L Riechmann; M Clark; H Waldmann; G Winter
Journal:  Nature       Date:  1988-03-24       Impact factor: 49.962
View more
  128 in total

1.  Design, Synthesis, and Biological Evaluation of Polyaminocarboxylate Ligand-Based Theranostic Conjugates for Antibody-Targeted Cancer Therapy and Near-Infrared Optical Imaging.

Authors:  Siyuan Ren; Xiang Sun; Haixing Wang; Trung Hai Nguyen; Negar Sadeghipour; Xiaochun Xu; Chi Soo Kang; Yujie Liu; Hua Xu; Ningjie Wu; Yanda Chen; Kenneth Tichauer; David D L Minh; Hyun-Soon Chong
Journal:  ChemMedChem       Date:  2018-11-26       Impact factor: 3.466

Review 2.  Can nanomedicines kill cancer stem cells?

Authors:  Yi Zhao; Daria Y Alakhova; Alexander V Kabanov
Journal:  Adv Drug Deliv Rev       Date:  2013-10-10       Impact factor: 15.470

3.  A theranostic "SMART" aptamer for targeted therapy of prostate cancer.

Authors:  Vittorio de Franciscis
Journal:  Mol Ther       Date:  2014-11       Impact factor: 11.454

Review 4.  Monoclonal antibodies in cancer immunotherapy.

Authors:  Ilgin Kimiz-Gebologlu; Sultan Gulce-Iz; Cigir Biray-Avci
Journal:  Mol Biol Rep       Date:  2018-10-11       Impact factor: 2.316

Review 5.  TGFβ in T cell biology and tumor immunity: Angel or devil?

Authors:  Eric Tu; Pei Zhi Cheryl Chia; Wanjun Chen
Journal:  Cytokine Growth Factor Rev       Date:  2014-07-29       Impact factor: 7.638

6.  An improved recombinant Fab-immunotoxin targeting CD22 expressing malignancies.

Authors:  Tapan K Bera; Masanori Onda; Robert J Kreitman; Ira Pastan
Journal:  Leuk Res       Date:  2014-07-05       Impact factor: 3.156

7.  Advances in targeted nanotherapeutics: From bioconjugation to biomimicry.

Authors:  Danielle M Valcourt; Jenna Harris; Rachel S Riley; Megan Dang; Jianxin Wang; Emily S Day
Journal:  Nano Res       Date:  2018-05-17       Impact factor: 8.897

8.  Emerging immune targets for the treatment of multiple myeloma.

Authors:  Atif Sohail; Adeela Mushtaq; Ahmad Iftikhar; Zabih Warraich; Sandra E Kurtin; Pavan Tenneti; Ali McBride; Faiz Anwer
Journal:  Immunotherapy       Date:  2018-02-01       Impact factor: 4.196

9.  A distinct subset of FcγRI-expressing Th1 cells exert antibody-mediated cytotoxic activity.

Authors:  Diana Rasoulouniriana; Nadine Santana-Magal; Amit Gutwillig; Leen Farhat-Younis; Yariv Wine; Corey Saperia; Lior Tal; Haim Gutman; Alexander Tsivian; Ronen Brenner; Eiman Abu Bandora; Nathan E Reticker-Flynn; Peleg Rider; Yaron Carmi
Journal:  J Clin Invest       Date:  2019-10-01       Impact factor: 14.808

Review 10.  Immunotoxins for leukemia.

Authors:  Alan S Wayne; David J Fitzgerald; Robert J Kreitman; Ira Pastan
Journal:  Blood       Date:  2014-02-27       Impact factor: 22.113
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.